What are the characteristic clinical features, histologic findings, and recommended treatment for discoid lupus erythematosus of the scalp?

Discoid Lupus Erythematosus of the Scalp: Pathognomonic Features

Discoid lupus erythematosus (DLE) of the scalp presents as well-demarcated erythematous plaques with firmly adherent scales, follicular plugging, central atrophy, and characteristic scarring that leads to irreversible alopecia. 1

Clinical Features

Primary Lesion Morphology

• Discoid plaques appear as sharply demarcated erythematous lesions with adherent scales or crusts that are difficult to remove 1
• Follicular keratotic plugs are pathognomonic and represent hyperkeratosis filling the follicular ostia 2, 3
• Central atrophy with peripheral hyperpigmentation develops as lesions mature 1
• Scarring alopecia is the irreversible end result, with complete loss of follicular openings 4, 3

Dermoscopic (Trichoscopic) Findings

The most diagnostically useful dermoscopic features in scalp DLE include:

• White structureless areas (62% of cases) representing fibrosis 3
• Arborizing vessels (57.8%) indicating inflammation 3
• Follicular keratotic plugs (47%) - highly specific when present 2, 3
• Absent follicular openings (45.8%) in scarred areas 3
• Perifollicular scaling (43.9%) surrounding hair follicles 3
• Speckled brown pigmentation (38%) from melanin incontinence 3

Histopathologic Findings

Essential Microscopic Features

Skin biopsy must be performed from the most active erythematous or sclerotic portion while the lesion remains clinically visible, as sampling healed lesions markedly reduces diagnostic yield. 5

The characteristic histologic triad includes:

• Interface dermatitis with vacuolar alteration of the dermo-epidermal junction 1
• Follicular hyperkeratosis and plugging corresponding to the clinical keratotic plugs 1, 2
• Superficial and deep perivascular/periadnexal lymphocytic infiltrate often with interstitial mucin 1

Additional features:

• Focal epidermal thinning alternating with hyperkeratosis 1
• Thickening of the epidermal basement membrane 1
• Dermal fibrosis in chronic lesions 1

Direct Immunofluorescence

• Immunoglobulin and complement deposits at the dermo-epidermal junction (lupus band test) 1
• IgG, IgA, IgM, and C3 deposition patterns should be evaluated 5

Recommended Treatment Algorithm

First-Line Mandatory Interventions

Photoprotection is mandatory for all DLE patients, requiring SPF 60+ sunscreen, sun avoidance, and protective clothing, as UV exposure triggers new lesions. 5

Smoking cessation must be strongly counseled, as smoking impairs antimalarial response. 5

Pharmacologic Management Sequence

Step 1: Topical + Systemic Initiation

• Start hydroxychloroquine as first-line systemic therapy for all scalp DLE not controlled with topical measures alone 5
• Apply high-potency topical corticosteroids to localized lesions while hydroxychloroquine reaches therapeutic effect (typically 6-12 weeks) 5

Step 2: Glucocorticoid Bridge (if needed)

• Use oral glucocorticoids at the lowest effective dose for the shortest duration to achieve initial disease control while hydroxychloroquine takes effect 5
• Begin tapering glucocorticoids as soon as hydroxychloroquine demonstrates efficacy 5

Step 3: Escalation for Refractory Disease

• Add immunosuppressive agents when patients fail to respond adequately to hydroxychloroquine plus glucocorticoids 5
• Consider immunosuppressives when glucocorticoids cannot be tapered below 7.5 mg/day prednisone equivalent 5

Comorbidity Prevention During Treatment

• Prescribe calcium and vitamin D supplementation for all patients on chronic glucocorticoid therapy 5
• Consider low-dose aspirin in patients receiving corticosteroids or those with antiphospholipid antibodies 5
• Screen aggressively for hypertension, dyslipidemia, and diabetes, as SLE patients have markedly increased cardiovascular risk 5

Monitoring Strategy

Baseline Assessment

• Perform skin biopsy with histology and direct immunofluorescence for diagnostic confirmation 5, 1
• Document disease extent using the Cutaneous Lupus Disease Area and Severity Index (CLASI) 6, 5
• Order comprehensive autoantibody panel (ANA, anti-dsDNA, anti-Ro/SSA, anti-La/SSB) and complement levels (C3, C4) to assess for systemic involvement 5

Follow-Up Monitoring

• Reassess CLASI score at each visit to quantify treatment response 6, 5
• Repeat biopsy if lesion morphology changes or treatment fails, to exclude malignant transformation 6
• Obtain annual ophthalmologic examination after 5 years of hydroxychloroquine therapy (yearly from start if high-risk) 6

Critical Pitfalls to Avoid

Do not delay biopsy until lesions have completely healed, as nonspecific histologic findings will fail to confirm the diagnosis. 5

Do not rely on serological markers alone to guide treatment escalation without clinical correlation, as this risks overtreatment. 5

Avoid prolonged high-dose glucocorticoids due to infection risk, osteoporosis, avascular necrosis, and cardiovascular complications. 5

Do not miss the opportunity to counsel on smoking cessation, as this single intervention significantly impacts treatment efficacy. 5